Orthopedic Non-Spinal Metallic Bone Screws and Washers – Performance Criteria for Safety and Performance Based Pathway
The U.S. Food and Drug Administration (FDA) has provided comprehensive guidance on adaptive designs for clinical trials in the development of drugs and biologics. This document, titled Adaptive Designs for Clinical Trials of Drugs and Biologics, offers a framework for pharmaceutical companies and researchers to implement adaptive trial designs while ensuring scientific validity and regulatory […]
510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review
The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety of medical products, including drugs, biologics, and medical devices. One of the key aspects of this responsibility is adverse event reporting, which helps identify potential risks and enhances patient safety. The FDA guidance document titled “Postmarketing Adverse Event Reporting for […]
Study Data Technical Conformance Guide – Technical Specifications Document
The U.S. Food and Drug Administration (FDA) plays a critical role in ensuring that drugs and biologics brought to market are both safe and effective. The agency’s guidance document, “Benefit-Risk Assessment for New Drug and Biological Products,” provides valuable insights into how regulatory decisions are made. This guidance, published to improve transparency, offers sponsors a […]
M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms
The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and efficacy of pharmaceutical products. One of its key areas of focus is safety signal management, which involves identifying, assessing, and mitigating risks associated with medicinal products. The FDA’s recent guidance document, “Safety Signal Management in Pharmacovigilance”, provides a structured […]
Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA
The U.S. Food and Drug Administration (FDA) has issued a guidance document titled “Computer Software Assurance for Production and Quality System Software,” aimed at modernizing the approach to software validation within the medical device industry. This guidance provides recommendations on risk-based assurance activities for computer software used in production and quality systems, aligning with FDA’s […]
Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development
The U.S. Food and Drug Administration (FDA) has released an essential guidance document titled “Postmarketing Safety Reporting for Combination Products.” This guidance provides clarity on regulatory expectations for manufacturers and applicants of combination products, ensuring patient safety through structured postmarketing safety reporting (PMSR). What Are Combination Products? Combination products integrate two or more regulated components […]
Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry
The U.S. Food and Drug Administration (FDA) has issued detailed guidance on the nonproprietary naming of biological products to enhance pharmacovigilance and ensure patient safety. The document, titled “Nonproprietary Naming of Biological Products”, provides essential insights into the FDA’s approach toward naming both originator biologics and biosimilars. Key Objectives of the FDA Guidance The primary […]
Patient-Focused Drug Development: Methods to Identify What Is Important to Patients
The U.S. Food and Drug Administration (FDA) has issued a comprehensive guidance document titled Adaptive Designs for Clinical Trials of Drugs and Biologics. This document serves as a roadmap for pharmaceutical companies, clinical researchers, and regulatory professionals, outlining best practices for incorporating adaptive design methodologies in clinical trials. What is an Adaptive Design? Adaptive design […]
Drug Product Tracing: The Effect of Section 585 of the FD&C Act
The U.S. Food and Drug Administration (FDA) has issued comprehensive guidelines on the mandatory reporting of serious adverse events associated with dietary supplements. This guidance, outlined in the document titled Guidance for Industry: Questions and Answers Regarding the Mandatory Reporting of Adverse Events for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug […]